Celltrion USA Announces Submission of BLA for Subcutaneous Infliximab Biosimilar  | Goodwin
On December 22, 2022, Celltrion USA announced that it submitted a Biologics License Application (BLA) for a subcutaneous formulation of infliximab, CT-P13, to the U.S. Food and Drug...
Source: jdsupra.com